Hero Background

LIFE SCIENCES

Discover, design, and deliver the right drug for the right patient

Tempus provides integrated solutions to help meet your needs from early discovery through commercialization.

We partner with scientists and researchers to accelerate the drug development process

  • 90%

    of the top 20 pharma oncology companies partner with Tempus

  • 200+

    biopharma partnerships

image description

Data Collaborations

  • 6M+

    de-identified research records to power scientific discovery to improve patient outcomes

  • 800K+

    records with matched clinical data linked with genomic information

  • ~200K

    records with whole transcriptome profiles

image description

Sequencing

  • 6

    NGS tests to support clinical trial and research sequencing

  • 6.5K+

    oncologists rely on Tempus as their precision medicine partner

image description

Clinical Trial Solutions

  • 10

    days on average to activate a new site

  • 200+

    provider networks and research institutions in the TIME Trial® Program

  • 26K+

    patients have been identified for potential enrollment into clinical trials in our network

image description
Our Impact

Thanks to Tempus, we are able to identify patients that can be helped with our proprietary TMod™ platform. Without them, we wouldn’t be able to do this.

William Go, SVP, Head of Development at A2 Biotherapeutics (TMod™ is a trademark of A2 Biotherapeutics)

Our Impact

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Learn more about our partnership with Genmab
Our Impact

Bayer’s strong focus in precision medicine combined with Tempus’ unique testing offering has culminated in this collaboration to bring genomic testing to cancer patients.

Bhavesh Ashar, Senior Vice President, Head of U.S. Oncology at Bayer

Learn more about our partnership with Bayer
Our Impact

Our partnership with Tempus will enable us to collect important retrospective information about the patients enrolled in the dose escalation part of our clinical trial that we can potentially use to inform enrollment in the expansion stage of our study.

Jorge DiMartino, Chief Medical Officer and Executive Vice President, Clinical Development at Kronos Bio

Learn more about our partnership with Kronos

Featured Resources

View all RESOURCES
  • UPCOMING WEBINAR:

    Q&A: Impact of multimodal data in translational science

    Analysis of real-world data (RWD) streamlines translational research and enables providers and researchers to provide precision medicine to patients at scale.

    Read more
  • UPCOMING WEBINAR:

    Q&A: Grow your clinical trial portfolio and increase enrollment with the TIME clinical trial network

    Jason Claes, Clinical Research Manager at TriHealth, shares his perspective on optimizing TIME to increase clinical trial enrollment.

    Read more
  • UPCOMING WEBINAR:

    An analysis on the utility of liquid biopsy (LBx) throughout clinical development

    Listen to industry leaders discuss longitudinal endpoints for disease progression, the evolving role of liquid biopsy within drug development, and the value of methylation in combination with liquid biopsy.

    Watch replay
  • UPCOMING WEBINAR:

    The value of RNA sequencing in drug discovery

    Learn the value of RNA Sequencing in identifying altered expression programs in tumors that are measurable by RNA-Seq but not DNA-Seq.

    Read more
  • UPCOMING WEBINAR:

    5 things to know when navigating clinical development and regulatory pathways for CDx

    Scientific and regulatory leaders from Tempus discuss how Tempus’ platform can enhance clinical development for CDx.

    Read more
  • UPCOMING WEBINAR:

    AACR GSK Product Theater

    The Tempus Spotlight Theater this year was on “Delivering on the Promise of Precision Medicine: Leveraging Diagnostics and Data to Drive Next-Generation Drug Development” and was a fireside chat between Kate Sasser, Chief Scientific Officer at Tempus and Anne-Marie Martin, SVP Global Head in the Experimental Medicine Unit at GSK.

    Watch now
  • UPCOMING WEBINAR:

    Tempus’ FDA approval and insights on the use of companion diagnostics in clinical development

    Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.

    Watch replay
  • UPCOMING WEBINAR:

    Leveraging Tempus AI and multimodal data to increase probability of technical success in Biopharma

    Advances in oncology treatments over the past 20 years have significantly extended patients’ life expectancy. From 2001 to 2020, cancer death rates dropped 27% [1]. However, there are still many unmet needs, which the life science community is working hard to address.

    Read more
  • UPCOMING WEBINAR:

    Using multimodal real-world data for decision-making

    Learn more about Gilead Sciences’ efforts to drive biomarker innovations and assemble their organization for integrated, data-driven research.

    Read more

Tempus empowers you to make smarter, faster, and more efficient decisions

Get customized solutions for your needs.